76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
P Pharming Group NV
P
Closed
1.04 2.77
Overview
Share price change
24h
Min
0.981
Max
1.053
Income | -18M -15M |
|---|---|
Sales | -14M 79M |
EPS | -0.02 |
Profit margin | -18.61 |
Employees | 404 |
EBITDA | 1.9M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +92.03% upside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | 87M 696M |
|---|---|
Previous open | -1.73 |
Previous close | 1.04 |
Pharming Group NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pharming Group NV Forecast
Price Target
By TipRanks
92.03% upside
12 Months Forecast
Average 1.997 EUR 92.03%
High 2 EUR
Low 2 EUR
Based on 1 Wall Street analysts offering 12 month price targets forPharming Group NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
